285 related articles for article (PubMed ID: 19073300)
1. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
[TBL] [Abstract][Full Text] [Related]
2. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.
Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Bhavnani SM; Ellis-Grosse E
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):155-9. PubMed ID: 19150707
[TBL] [Abstract][Full Text] [Related]
3. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
Kispal B; Walker SAN
Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
6. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
Meagher AK; Passarell JA; Cirincione BB; Van Wart SA; Liolios K; Babinchak T; Ellis-Grosse EJ; Ambrose PG
Antimicrob Agents Chemother; 2007 Jun; 51(6):1939-45. PubMed ID: 17353238
[TBL] [Abstract][Full Text] [Related]
7. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis.
Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH
Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285
[TBL] [Abstract][Full Text] [Related]
8. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.
Zelenitsky SA; Ariano RE
J Antimicrob Chemother; 2010 Aug; 65(8):1725-32. PubMed ID: 20558470
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
Koomanachai P; Kim A; Nicolau DP
J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
[TBL] [Abstract][Full Text] [Related]
11. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
Conte JE; Golden JA; Kelly MG; Zurlinden E
Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
[TBL] [Abstract][Full Text] [Related]
18. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
[TBL] [Abstract][Full Text] [Related]
19. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
DeRyke CA; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
[TBL] [Abstract][Full Text] [Related]
20. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
